Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: Using viral dynamic models that incorporate drug susceptibility and adherence

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 33, Issue 4, 2006, Pages 399-419

  Wu, Hulin ^a   Huang, Yangxin ^b   Acosta, Edward P ^c   Park, Jeong Gun ^d   Yu, Song ^d   Rosenkranz, Susan L ^d   Kuritzkes, Daniel R ^e   Eron, Joseph J ^f   Perelson, Alan S ^g   Gerber, John G ^h  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g LOS ALAMOS NATIONAL LABORATORY   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; AIDS; Antiretroviral therapy; Compliance; Drug exposures; Drug resistance; Hierarchical Bayesian models; HIV 1 infection; Pharmacodynamics; Pharmacokinetics; Viral dynamic models

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; VIRUS RNA;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CLINICAL STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LOW DRUG DOSE; MATHEMATICAL MODEL; MULTIVARIATE ANALYSIS OF COVARIANCE; NONLINEAR SYSTEM; PATIENT COMPLIANCE; PHARMACODYNAMICS; PILL; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ALGORITHMS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BAYES THEOREM; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; MODELS, BIOLOGICAL; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; T-LYMPHOCYTES; VIRAL LOAD;

EID: 33745602749     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-006-9006-4     Document Type: Article

References (31)

1. N. Buss and N. Cammack. Measureing the effectiveness of antiretroviral agents. Antiviral Ther. 6:1-7 (2001).
2. Y. Huang, D. Liu and H. Wu. Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system. Biometrics 2006; In press.
3. H. Wu, Y. Huang, E. P. Acosta, S. L. Rosenkranz, D. R. Kuritzkes, J. J. Eron, A. S. Perelson and J. G. Gerber. Modeling long-term HIV dynamics and antiretroviral response: Effects of drug potency, pharmacokinetics, adherence and drug resistance. J. Acquir. Immune Defic. Syndr. 39:272-283 (2005).
4. E. P. Acosta, H. Wu, A. Walawander, J. Eron, C. Pettinelli, S. Yu, D. Neath, E. Ferguson, A. J. Saah, D. R. Kuritzkes and J. G. Gerber for the Adult ACTG 5055 Protocol Team. Comparison of two indinavir/ritonavir regimens in treatment-experienced HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 37:1358-1366 (2004).
5. A. Molla, M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck and D. J. Kempf. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766. (1996).
6. Y. Huang, S. L. Rosenkranz and H. Wu. Modeling HIV dynamics and antiviral responses with consideration of time-varying drug exposures, sensitivities and adherence. Math. Biosci. 184:165-186 (2003).
7. J. R. Ickovics and A. W. Meisler. Adherence in AIDS clinical trial: a framework for clinical research and clinical care. J. Clin. Epidemiol. 50:385-391 (1997).
8. A. S. Perelson and P. W. Nelson. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev. 41:3-44 (1999).
9. H. Wu and A. A. Ding. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 55:410-418 (1999).
10. A. A. Ding, H. Wu. Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. Biostatistics 2:13-29 (2001).
11. D. D. Ho, A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard and M. Markowitz. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126 (1995).
12. A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard and D. D. Ho. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586 (1996).
13. A. S. Perelson, P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, D. D. Ho. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191 (1997).
14. X. Wei, S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag and G. M. Shaw, Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122 (1995).
15. N. M. Dixit, M. Markowitz, D. D. Ho and A. S. Perelson. Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antiviral Ther. 9:237-246 (2004).
16. L. B. Sheiner. Modeling pharmacodynamics: parametric and nonparametric approaches. In Variability in Drug Therapy: Description, Estimation, and Control. Rowland M et al. (ed.) Raven Press, New York, pp139-152, 1985.
17. D. J. Kempf, A. Hsu and P. Jiang et al. Response to ritonavir intensification in indinavir recipients is highly correlated with virtual inhibitory quotient. In 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA. Abstract 523, (2001).
18. M. Boffito, D. J. Back, L. F. Blaschke, M. Rowland, R. J. Bertz, G. J. Gerber, V. Miller. Roundtable report: protein binding in antiretroviral therapies. AIDS Res. Hum. Retroviruses 19:825-835 (2003).
19. N. Shulman, A. Zolopa, D. Havlir, A. Hsu, C. Renz, S. Boller, P. Jiang, R. Rode, J. Gallant, E. Race, D. J. Kempf and E. Sun. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob. Agents Chemother. 46:3907-3916 (2002).
20. The Pacific AIDS Education and Training Center. Pharmacokinetics of Protease Inhibitors, Website: http://www.hivtools.com/PI.php.
21. H. Wu, D. R. Kuritzkes, D. R. McClernon, H. Kessler, E. Connick, A. Landay, G. Spear, M. Heath-Chiozzi, F. Rousseau, L. Fox, J. Spritzler, J. M. Leonard and M. M. Lederman. Characterization of viral dynamics in Human Immunodeficiency Virus Type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration and virological endpoints. J. Infect. Dis. 179:799-807 (1999).
22. D. W. Notermans, J. Goudsmit, S. A. Danner, F. de Wolf, A. S. Perelson and J. Mittler. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. Acquir. Immune Defic. Syndr. 12:1483-1490 (1998).
23. M. Markowitz, M. Louie, A. Hurley, E. Sun, M. D. Mascio, A. S. Perelson and D. D. Ho. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol. 77:5037-5038 (2003).
24. C. Han, K. Chaloner and A. S. Perelson. Bayesian analysis of a population HIV dynamic model. Case Studies in Bayesian Statistics, Vol. 6. Springer-Verlag, New York, 2002.
25. M. Davidian and D. M. Giltinan. Nonlinear Models for Repeated Measurement Data. Chapman & Hall, London, 1995.
26. M. A. Nowak and R. M. May. Virus Dynamics: Mathematical Principles of Immunology and Virology. Oxford University Press, Oxford, 2000.
27. D. Gamerman. Markov Chain Monte Carlo: Stochastic Simulation for Bayesian Inference. Chapman & Hall, London, 1997.
28. J. C. Wakefield. The Bayesian approach to population Pharmacokinetic models. J. Am. Statist. Assoc. 91:61-76 (1996).
29. R. H. Haubrich, C. A. Kemper, N. S. Hellman, P. H. Keiser, M. D. Witt, D. N. Forthal, J. Leedom, M. Leibowitz, J. M. Whitcomb, D. Richman, J. A. McCutchan. and California Collaborative Treatment Group. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. Acquir. Immune Defic. Syndr. 16:F33-F40 (2002).
30. K. C. Zachary, G. J. Hanna and R. T. D'Aquila. Human Immunodeficiency Virus Type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo. Clin. Infect. Dis. 33:2075-2077 (2001).
31. R. Schooley, R. Haubrich and M. Thompson. et al. Effect of amprenavir hyper-susceptibility on the response to APV/ritonavir-based therapy in ART-experienced adults selected by baseline susceptibility (ESS40006): 24-week data. The 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, Boston, MA, USA. Abstract 143, 2003.